当前位置： X-MOL首页 › 行业资讯 › 罗氏与联合利华讲座｜畅聊企业界的那些事

罗氏与联合利华讲座｜畅聊企业界的那些事

作者：X-MOL 2024-04-17

在庆祝 RSC Student Club 项目启动 10 周年之际，我们将于 🔗 Student Week 期间组织第九期会士大讲堂（4 月 26 日下午），特邀联合利华王进防博士（上海研发中心美妆及个人护理品科技研发总监）和罗氏沈宏博士（罗氏中国创新中心负责人和高级副总裁）作为主讲嘉宾，与大家共同探讨“企业界的那些事”。

目前活动已开通参会注册并同时征集“与会士对话”线上参与嘉宾，名额有限，报名截止日期为 4 月 17 日。请往下翻阅，扫码锁定席位!

与会士对话

你是否对自己未来的职业发展感到迷茫？

你是否想了解企业和高校科研有哪些异同？

你是否渴望获得更多来自资深人士的职业指导与建议？

如果“是”的话，那么这场讲座绝对是你不可错过的好机会！除精彩的报告外， “与会士对话”环节中，我们将为相关领域的科研工作者提供线上对话机会，与主讲人、主持人、RSC 工作人员一起探讨你所关心的“企业界那些事”，诚邀您的参与！（划重点：如果您希望被选为“与会士对话”嘉宾，请在 4 月 17 日前注册，并提出您感兴趣的问题。）

受邀嘉宾

王进防 FRSC

联合利华上海研发中心

讲座题目：REGENERATE TECHNOLOGY - 从科学研究到产品研发

Dr. Jin fang Wang, FRSC, Beauty&Wellbeing and Personal Care Sci &Tech Director, Unilever R&D Center, Shanghai. He got his PhD in Analytical Chemistry from Dalian Institute of Chemical physics, Chinese Academy of Science in 1999 and his second PhD in Material Science from University of Strathclyde, UK in 2003. His research areas now focus on developing planet-positive ingredients cosmetically repair and enhance properties and function of substrates to fulfill consumers' unmet needs in Beauty and Personal Care products e.g. novel biomineralisation materials for enamel health for oral care products, novel antipersiperant technology for deo products, design and application of sustainable/functional materials/ingredients for Skin and Hair Care products with 50+patent applications and product launches in markets.

沈宏 FRSC

罗氏中国创新中心

讲座题目：漫谈”肝癌药物研发”和合作与创新

Hong Shen received his B.S. from Peking University and Ph.D. from Stanford University. After 9 years working at Merck, Dr. Shen joined the Roche R&D Center in Shanghai in Jan. 2012. He is currently Senior Vice President and Head of China Innovation Center of Roche (CICoR), an integrated drug discovery and early clinical development center of excellence. Dr. Shen has extensive drug discovery experience in the therapeutic areas of oncology, immunology, antiviral, antibiotics, hypertension, diabetes, thrombosis, atherosclerosis, and obesity. His teams have made major contributions to 12 clinical compounds and 19 preclinical candidates. Dr. Shen also contributed to certain early clinical development programs.

Dr. Shen contributed to more than 110 publications and almost 120 patent applications. He is a Fellow of the Royal Society of Chemistry (FRSC), an extended core member of the R&D-based Pharmaceutical Association Committee (RDPAC) in China, a member of the AACR Chemistry in Cancer Research Working Group (CICR) Steering Committee, and a Steering Advisory Board Member of the Roche Accelerator. Dr. Shen is a recipient of the Zhangjiang Outstanding Innovation and Entrepreneurship Award, the Leo Sternbach Award, and Roche pRED Inventor’s Recognition Gold Medal.